Attendee Confcal 2 Welcome Box
Browsing Over 913 Presentations
The search for a CUP: Specific molecular signature (ID 1298)
Managing patients with CUP: The ESMO Clinical Practice guidelines (ID 1299)
Strategies of molecular identification of the tissue of origin: Perceived value and ongoing research (ID 1296)
Targeting key oncodrivers in CUP (ID 1297)
Tumour-agnostic precision therapeutics: The concept and key successes in clinical practice (ID 1301)
Implementing NGS multiplex testing for actionable biomarkers in solid tumours (ID 1302)
Challenges in the development of tumour-agnostic targeted agents (ID 1303)
Tumour-agnostic therapies: Considerations on generation of evidence frameworks (ID 1304)
Academic research contributions in oncology drug development (ID 1306)
The development and implementation of biosimilars in the era of personalized cancer medicine (ID 1307)
Pharmacogenetics in the practice of molecular oncology: Value or luxury? (ID 1308)
The value of RWE for assessing safety and effectiveness of targeted agents in cancer (ID 1309)
